Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma
This study is currently recruiting participants.
Study NCT00581919 Information provided by University of Wisconsin, Madison
First Received: December 19, 2007 Last Updated: September 14, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Myeloma
Additional conditions recognized in this trial
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Additional drug interventions recognized in this trial
Acetylcarnitine
Bortezomib
Carnitine
Dexamethasone
Dexamethasone acetate
Doxorubicin
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Micronutrients
Molecular Mechanisms of Pharmacological Action
Nootropic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Vitamin B Complex
Vitamins
Sponsors listed in this trial
University of Wisconsin, Madison
Back to top of Main Content
